SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?


To: Sir Auric Goldfinger who wrote (10725)11/12/2002 6:37:08 AM
From: RockyBalboa  Respond to of 19428
 
it's true...


GOODWILL

Goodwill from acquisitions represents the excess of purchase price paid over the value of net assets acquired.
The Company does not amortize goodwill resulting from acquisitions after June 30, 2001, but it is the Company's
policy to assess periodically the carrying amount of its goodwill and purchased intangible assets to determine if
there has been an impairment to their carrying value. Based on the inability to generate positive cash flows in
Inter-Tel.NET since its acquisition, the Company recorded a charge of $7,984,806 to write-off the carrying value
of the goodwill related to that acquisition. See Note B.

NOTE B: ACQUISITIONS

INTER-TEL.NET

On July 24, 2001, the Company purchased 83% of Inter-Tel.NET, Inc. ("ITN") from Inter-Tel, Inc. in a stock
purchase transaction. ITN is a facilities-based provider of U.S. originated international long-distance voice and data
terminations services. The efficiency of its managed VoIP network, its least cost routing structure and bandwidth
capacity allow CSC to offer competitive prices to carrier and reseller customers for international termination.

NOTE D: NOTES PAYABLE

INTER-TEL, INC.

The Company has a note payable in the amount of $4,950,000 to Inter-Tel, Inc. as consideration for the purchase of an
83% interest in Inter-Tel.NET from Inter-Tel, Inc. Inter-Tel, Inc. owned 17% of CSC until the transaction with
Vianet (see Note B) at which time Inter-Tel, Inc. took stock of the combined entity. The note is collateralized in
part by stock and other marketable securities and 100% of the net assets of Inter-Tel.NET. The note was originally
due and payable with a principal payment of $250,000 due sixty (60) days from July 24, 2001 but later modified to
provide for a later payment date for the initial payment; then interest only due and payable from October 16, 2001
through July 15, 2002; then monthly principal and interest payments based on 1% of collected monthly revenues from
July 16, 2002 to October 15, 2002 and based on 2% of collected monthly revenues from October 16, 2002 until paid
in full. The note is due and payable on December 31, 2007, or earlier in the event of default or a "change of control"
of the purchased entity. The interest rate for the note is 6% per annum.

ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.

The following table sets forth information regarding ownership of the Company's Common Stock as of April 7, 2002, by (i) each person known by the Company to beneficially own more than five percent (5%) of Vianet's outstanding shares of common stock, (ii) each director of the Company, and (iii) all directors and executive officers of the Company as a group.



NAME AND ADDRESS OF SHARES OF PERCENT OF
BENEFICIAL OWNER TITLE COMMON STOCK CLASS
-------------------------------------------------------------------------------------------------------------

Jeremy T.G. Posner* Chairman, Secretary and Director (a) 8,175,469 1.43%

Gregory A. Somers* President and Director 156,003,929 27.33%

Peter Ianace* Chief Executive Officer and Director (b) 4,636,293 0.81%

Victor E. Goetz - Senior Vice President, Chief Financial 28,682,337 5.03%
1266 West Paces Ferry Officer, Chief Compliance Officer,
Rd, #179, Atlanta, GA 30327 Assistant Secretary & Director



- 28 -

--------------------------------------------------------------------------------


NAME AND ADDRESS OF SHARES OF PERCENT OF
BENEFICIAL OWNER TITLE COMMON STOCK CLASS
-------------------------------------------------------------------------------------------------------------

Robert Logan* Senior Vice President and Chief (c) 221,791 0.04%
Operating Officer

Brian Berger* Chief Technology Officer & Vice (d) 105,045 0.02%
President of Engineering

Robert Thompson* Vice President, Sales (e) 30,000 0.01%

Stephen M. Wagner* Director 17,489,230 3.06%

All officers, directors and 215,344,094 37.52%
key executives (8 Persons)

Inter-Tel Inc 59,463,381 10.42%
120 N 44TH ST, Suite 200,
Phoenix, AZ 85034-1822
tel. 602-302-8900

Dennis D. Somers 30,081,475 5.27%
4785 240th Ave., Webb, Iowa
51366

Mike Moehle 28,682,337 5.03%
3909 River Pl Blvd Austin TX
78730

Seneca Capital L.P. - 527 (f) 59,667,560 10.35%
Madison Avenue, 11th Floor,
New York, NY 10022



* c/o Vianet Technologies, Inc. - 6509 Windcrest Drive, Suite 160, Plano,
TX 75024

(a) Includes (i) 13,627 shares of common stock, (ii) 250,000 shares of common stock underlying options exercisable at $.10 per share, all of which are currently exercisable, (iii) warrants to purchase 32,520 shares of common stock, exercisable at $5.00 per share, all of which are currently exercisable (iv) 7,846,558 shares of common stock owned indirectly through Xelix Capital Limited, an entity controlled by Mr. Posner, and (v) 32,764 shares of common stock owned indirectly through Eastbrook Systems, an entity controlled by Mr. Posner.

- 29 -

--------------------------------------------------------------------------------
(b) Includes (i) 1,769,626 shares of common stock, (ii) 166,667 shares of common stock underlying options all of which are currently exercisable, (iii) 350,000 shares of common stock and warrants to purchase an additional 350,000 shares of common stock, all of which are currently exercisable, underlying convertible notes, and (iv) 2,000,000 shares of common stock underlying warrants owned by Espre, Inc., an entity controlled by Mr. Ianace, all of which are currently exercisable. Excludes 833,333 shares of common stock underlying options, which are not currently vested or exercisable.
(c) Includes (i) 196,791 shares of common stock and (ii) 25,000 shares of common stock underlying options, all of which are currently exercisable. Excludes 475,000 shares of common stock underlying options, which are not currently vested or exercisable.

(d) Includes (i) 45,045 shares of common stock and (ii) 60,000 shares of common stock underlying options, all of which are currently exercisable. Excludes 445,000 shares of common stock underlying options, which are not currently vested or exercisable.

(e) Includes 30,000 shares of common stock. Excludes 200,000 shares of common stock underlying options, none of which are currently vested or exercisable.

(f) Includes (i) 18,555,916 shares of common stock and (ii) 1,950,971 shares of common stock underlying warrants owned by Seneca Capital L.P., all of which are currently exercisable. In addition, includes (iii) 35,440,216 shares of common stock and (iv) 3,720,457 shares of common stock underlying warrants owned by Seneca Capital International, Ltd., all of which are currently exercisable.

- 30 -



To: Sir Auric Goldfinger who wrote (10725)11/12/2002 9:22:53 AM
From: who cares?  Respond to of 19428
 
The good ol call in the certs campaign, hallmark of quality.

quote.bloomberg.com

Endovasc Announces Shareholder and Dividend Alert

Business Editors & Health/Medical Writers

MONTGOMERY, Texas--(BUSINESS WIRE)--Nov. 12, 2002--Endovasc (OTCBB:ENVC) - a biotechnology company with two new cardiovascular drugs approved for final FDA phase III trials -announced today that it has -- in the opinion of its consultants -- uncovered an oversold position in excess of 1,000,000 shares in the company's stock, held primarily by The Charles Schwab Corp. (NYSE:SCH), Ameritrade (Nasdaq:AMTD) and Refco. The findings are a result of an ongoing litigation intelligence work conducted in connection with the $216 million stock manipulation lawsuit filed by Endovasc and accepted on contingency basis by the legendary trial attorney John O'Quinn, who also won the record $17.3 billion dollar settlement for the State of Texas vs. Big Tobacco.

"The oversold position in our company's stock can actually be great news for our shareholders," says Dr. David P. Summers, Chairman and Chief Executive Officer of Endovasc. "The overselling in our stock in the past few weeks does not seem to have had a negative impact on our share price. But, if shareholders actually asked for physical delivery of the shares they bought, the market would probably have to pay a premium in order to deliver them."

"Additionally, our Board has recently approved the issuance of a tracking stock dividend plan. But according to our plan, as approved, it won't be possible to issue any dividends to anyone that the company can't identify as a legal beneficial shareholder. This is why it is imperative that our shareholders contact their brokers to ask their stock to be taken out of the street form and put into physical form," states Summers.

Endovasc's flagship drug Angiogenix(TM) is a revolutionary new cardiovascular drug that has been proven to recruit the body's own stem cells that help grow new heart vessels predicted to relieve chest pain and improve heart function. Angiogenix(TM) is a simple, small molecule derived from the tobacco plant that, when given in low doses, has demonstrated remarkable results in stimulating robust growth of new vessels in four different animal experiments with simulated blood-flow deficiencies, suggesting that it will do the same in a human patient's heart and limbs.

The treatment covered in the patent is licensed to Endovasc on exclusive basis for 10 years. In the most recent animal feasibility modal using Angiogenix for treatment of chronic myocardial ischemia, all subjects' demonstrated signs of new renewed blood flow at 4 to 5 weeks post treatment. The study proved that Angiogenix(TM) is safe and more effective than anything else on the angiogenesis horizon - with the potential of becoming a biological alternative to a by-pass surgery. The most recent research results were publicized during an oral presentation at the recent 49th Annual World Wide Conference of the American College of Angiology (ACA) in Maui, Hawaii where Endovasc's CEO, Dr. David P. Summers, PhD, FACA presented a summary of the results of animal experiments to date.

In a lively discussion regarding the therapeutic benefits of low-dose nicotine, Sessions Chairman Dr. Robert B. Kalmansohn, Past President of the ACA, and Emeritus Professor of Clinical Medicine and Cardiology at UCLA and Attending Physician at Cedars Sinai Hospital in Los Angeles commented to the effect, "... if this potential therapy continues to demonstrate safety and efficacy as was demonstrated...it may become one of the greatest benefits to cardiovascular disease in the 21st century."

Endovasc's ANGIOGENIX(TM) treatment is currently the only viable angiogenesis treatment approved for submission of final FDA review for Phase III trials. The company is well ahead of all other biotech firms in bringing an angiogenesis drug to the market. The company's larger competitors, Genentech (NYSE:DNA) and Genzyme (Nasdaq:GENZ) are still in Phase II trials with their angiogenesis treatments and are experiencing various challenges, whereas Endovasc's treatment has repeatedly demonstrated that Angiogenix(TM) consistently produces a dose-related response and is a predictable drug.

How can you ensure that you receive future Endovasc's dividends?

Have your broker, who you bought your Endovasc shares through, request physical delivery of your share certificates. By doing so, you can become eligible for future dividends. Endovasc will be announcing shortly an update on future dividends and provide further assistance for its shareholders.

About the oversold position

Oversold condition information is based on member participant listings from the Depository Trust Corporation ("DTC") of those brokerage houses and clearing agents who purport to own share in the capital of the company. In addition, the company has received a similar shareholding accounting by its Member Participants through its shareholder proxy agent, Automatic Data Processing (ADP). The comparison indicates that on October 4, 2002, the DTC held a net deficiency of 1,005,299 shares less than that indicated by the true shareholder listing provided by ADP. Of these, Charles Schwab represents 445,972, Refco Securities 203,314 and Overtrade 119,756.

About Endovasc

Endovasc's phase III products include Angiogenix(TM), a uniquely potent small molecule derived from the natural tobacco plant that has shown to stimulate angiogenesis (growth of new blood vessels in the patient's heart) and recruit the body's own stem cells. It is predicted to become the first angiogenic agent approved to relieve chest pain and improve heart function via angiogenesis. The company's other phase III product is Liprostin(TM), a naturally occurring liposomal prostaglandin-based treatment that studies suggest will prevent restenosis (re-blockage of arteries), increase circulation, and reduce leg pain due to poor blood flow. Each of these products has market potential of over $1 billion annually.

Endovasc Ltd., Inc., established in 1996, is a biotechnology company focused in the area of cardiovascular disease, pioneering drug delivery technology designed to deliver and release drugs to their intended targets in an efficient and controlled manner. The company's products and processes include Liprostin(TM), ANGIOGENIX(TM) (Nicotine Receptor Agonist), PROStent(TM) stent-coating technology, and a biodegradable resorbable prosthesis.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc, please visit www.endovasc.com. (Investor questions and requests for materials can be submitted online.) To sign up for Endovasc shareholder alerts, please visit endovasc.com.

--30--LC/na*

CONTACT: Endovasc Ltd. Inc., Montgomery

Lana Copeland, 936/448-2222

Fax: 936/582-2250

InvestorRelations@endovasc.com

endovasc.com

KEYWORD: TEXAS

INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY DIVIDEND

SOURCE: Endovasc Ltd. Inc.

Today's News On The Net - Business Wire's full file on the Internet

with Hyperlinks to your home page.

URL: businesswire.com

-0- Nov/12/2002 12:30 GMT



To: Sir Auric Goldfinger who wrote (10725)11/12/2002 3:12:08 PM
From: who cares?  Read Replies (1) | Respond to of 19428
 
It just keeps getting better

JAGfn Rumors

TUESDAY , NOVEMBER 12, 2002 02:54 PM

Nov 12, 2002 (JAGfn.com via COMTEX) -- ENDOVASC LTD INC (ENVC)$2.23. Rumor that major short position will be bought in open market.

Copyright 2002 JAGfn.com All Rights Reserved